Agriterra moots sugar move 03/07/2009
Phil Edmonds’ African food group Agriterra expects a turnaround to profits as it contemplates a move into sugar.
Silence mute on rumours
Gene specialist Silence Therapeutics would not comment today on City suggestions of a major drug group tie-up.
Drug giant AstraZeneca holds nearly three per cent of Silence, a leading specialist in RNA (ribonucleic acid) interference, which can repress genes linked to the onset of disease. The Square Mile is abuzz with suggestions that Astra or another major pharmaceutical concern is interested in a corporate deal.
Finance director Melvyn Davies says the company is ‘in talks at all times’ about potential product licensing deals. A Silence adviser insists the company does not comment on rumours.
At 108p, this former growth stock retains some speculative appeal.
Subscribe today
Growth Company Investor subscribers have full access to all our AIM and small-cap share recommendations.
To subscribe today with a half-price offer and gain immediate access to all the recommendations, click here.
Advertisement
Xforex proudly presents a great opportunity
Get 20% bonus on your first deposit and a financial advisor serving you 24/7. For experienced traders – xforex extreme feature – follow our top trader LIVE!
New Issues on Aim Research Report 2009
The new survey into new AIM companies focusing on IPO activity over the closing months of 2008. The report itself contains information on the brokers who are most able to raise cash in the current environment and the sectors that are attracting institutional investment. Buy the new issues on Aim research report.
Liquidity Drivers on AIM research
In the first ever deep analysis of trading values and volumes on AIM, Growth Company Investor, in association with BDO Stoy Hayward, will be shining their research light on the pre-eminent companies on AIM. Buy the Liquidity Drivers on AIM research report today.
Spotlight on AIM 2009 research
The fifth annual examination of the entire AIM market, detailing the fastest growing companies on the junior market, aswell as the most profitable and the least profitable businesses. Buy the Spotlight on AIM 2009 research report today.
Cash Shells Special Report 2009
Business XL, the award-winning monthly magazine for growing companies, is delighted to announce the launch of a new study on cash shells. The research provides a comprehensive overview of cash shells on AIM, companies that have become a significant feature on the AIM landscape. Buy Cash Shells 2009 Research Report today.
Popular News
Aim
Boardroom Moves
Breaking-even
Buy
Cash
Commodities
Credit Crunch
Deals & Contracts
Debt
Defensive
Director Dealing
Dividends
Downgrades
Emerging Markets
Fundraisings
Growth Stocks
Mergers & Acquisitions
New Issues
Penny Shares
Plus Markets
Profit Warnings
Renewables
Restructuring
Speculative Punts
Technology
Turnaround
Undervalued
Advertisement
Latest News
Bglobal wins funding 03/07/2009
‘Smart metering’ specialist Bglobal has obtained up to £15 million asset funding from Barclays Asset Sales & Finance.
Jubilee in £26m Braemore bid 03/07/2009
Jubilee Platinum is offering shares to buy fellow AIM counter, smelting and refining specialist Braemore Resources.
Sectors
Aerospace & Defence
Automobiles & Parts
Banks
Beverages
Chemicals
Construction & Materials
Electricity
Electronic & Electrical Equipment
Equity Investment Instruments
Fixed Line Telecommunications
Food & Drug Retailers
Food Producers
Forestry & Paper
Gas, Water & Multiutilities
General Financial
General Industrials
General Retailers
Health Care Equipment & Services
Household Goods
Industrial Engineering
Industrial Metals
Industrial Transportation
Leisure Goods
Life Insurance
Media
Mining
Mobile Telecommunications
Nonequity Investment Instruments
Nonlife Insurance
Oil & Gas Producers
Oil Equipment, Services & Distribution
Personal Goods
Pharmaceuticals & Biotechnology
Real Estate
Software & Computer Services
